Tissue transglutaminase inhibition as treatment for diabetic glomerular scarring: it's good to be glueless.
Diabetic nephropathy is characterized by enhanced glomerular and tubulointerstitial deposition of extracellular matrix proteins, which are bound together by tissue transglutaminase (TG2). Huang et al. demonstrate that infusion of a novel TG2 inhibitor in diabetic rats prevented renal scarring and albuminuria and preserved glomerular filtration rate. These studies confirm the role of TG2 in the pathogenesis of diabetic nephropathy and add to an emerging literature that demonstrates that TG2 is an attractive therapeutic target for sclerosing kidney diseases.
Schelling
Jeffrey R
JR
Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA. jeffrey.schelling@case.edu
D000818:Animals; D002921:Cicatrix / Q000188:drug therapy*; D003928:Diabetic Nephropathies / Q000188:drug therapy / Q000473:pathology*; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D019204:GTP-Binding Proteins; D006801:Humans; D007678:Kidney Glomerulus / Q000473:pathology*; D000091345:Protein Glutamine gamma Glutamyltransferase 2; D051381:Rats; D011503:Transglutaminases / Q000037:antagonists & inhibitors* / Q000502:physiology
D004791:Enzyme Inhibitors; C000717609:Tgm2 protein, rat; D000091345:Protein Glutamine gamma Glutamyltransferase 2; D011503:Transglutaminases; D019204:GTP-Binding Proteins